Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: Pharmaceuticals were produced and distributed with active ingredients not manufactured according to Good Manufacturing Practices.
| Distributed by / for | UDL Laboratories, Inc., Rockford, IL 61103 |
| NDC | 51079-451-20 |
| Full product label | Amlodipine Besylate Tablets, USP, 5 mg*, packaged in a) 100-count (10 x 10) unit dose blisters per carton, NDC 51079-451-20; b) 300-count (10 x 30) unit dose blisters per carton, NDC 51079-451-56, c) 25-count (25 x 1) Robot-Rx Ready Packages in a carton, NDC 51079-451-19; and d) 30-count tablets per dosage card in a carton, NDC 51079-451-69, Rx only, Manufactured by: Mylan Pharmaceuticals Inc., Morgantown, WV 26505; Packaged and Distributed By: UDL Laboratories, Inc., Rockford, IL 61103. |
| Recalling firm | Mylan Institutional, Inc. (d.b.a. UDL Laboratories) |
| Distribution | Nationwide, Puerto Rico and Guam |
| Quantity | a) 42,733 cartons; b) 3,267 cartons; c) 10,303 cartons; d) 4,262,856 cartons |
| Recall initiated | 2013-09-17 |
| Report date | 2016-08-31 |
| Recall completed | 2018-04-24 |
| Recall number | D-1467-2016 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Rockford IL United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗